Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial

双氯芬酸 医学 耐受性 布洛芬 安慰剂 麻醉 加药 不利影响 养生 安慰剂对照研究 外科 内科学 双盲 药理学 病理 替代医学
作者
R.-L. Dreiser,Marc Marty,Elisabeta Ionescu,M.H. Gold,J H Liu
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag Dr. Karl Feistle]
卷期号:41 (09): 375-385 被引量:42
标识
DOI:10.5414/cpp41375
摘要

To assess efficacy and safety of diclofenac-K 12.5 mg tablets in the treatment of acute low back pain (low back pain).A multiple dose, double-blind, double-dummy, randomized, placebo-controlled, parallel group trial compared diclofenac-K (12.5 mg; n = 124) with ibuprofen (200 mg; n = 122) and placebo (n = 126) in patients with moderate-to-severe acute low back pain. The treatment consisted of an initial dose of 2 tablets followed by 1 or 2 tablets every 4-6 hours as needed (maximum 6 tablets/day) for 7 days. The primary efficacy outcome for the initial dose was TOTPAR-3, the summed total pain relief over the first 3 hours. Secondary initial dose outcomes included TOTPAR-6, summed pain intensity differences SPID-3 and SPID-6, time to rescue medication or remedicate, and the End of First Dose global efficacy assessment. The primary efficacy outcome for the flexible multiple dosing regimen was the End of Study global efficacy assessment. Secondary outcomes for multiple dosing included time to rescue medication over the entire study, the End of Day global efficacy assessments (daily over Days 1-7), pain intensity differences on the VAS measured at Visit 2 and 3, and change in Eifel algofunctional index. Safety/tolerability was assessed by recording adverse events.Diclofenac-K 12.5 mg demonstrated superiority vs placebo on the primary efficacy parameter and almost all secondary initial dose outcomes. With respect to the initial dose, diclofenac-K 12.5 mg was also significantly superior to ibuprofen 200 mg on SPID-3. Ibuprofen 200 mg was superior to placebo only on the End of First Dose global efficacy assessment. The flexible multiple dosing regimens of diclofenac-K and ibuprofen were both significantly superior to placebo on the End of Study global efficacy assessment, time to rescue medication over the entire study period, the End of Day global efficacy assessment on Days 1-2, pain intensity difference on the VAS at Visit 3 and the Eifel algofunctional index at Visit 3 (also at Visit 2 in diclofenac-K 12.5 mg group). Both active treatments were as well tolerated as placebo.The flexible multiple dosing regimen of diclofenac-K 12.5 mg (initial dose of 2 tablets followed by 1-2 tablets every 4-6 hours, max. 75 mg/day) is an effective and safe treatment of acute low back pain.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
研友_Zl1w68发布了新的文献求助10
刚刚
脑洞疼应助王得胜采纳,获得10
刚刚
1秒前
1秒前
sun发布了新的文献求助10
1秒前
liu发布了新的文献求助10
2秒前
3秒前
Accepted给动听的夏真的求助进行了留言
3秒前
3秒前
4秒前
4秒前
4秒前
等待鑫鹏发布了新的文献求助10
5秒前
5秒前
在水一方应助rexfang采纳,获得30
5秒前
5秒前
6秒前
6秒前
6秒前
6秒前
研友_ndDY5n发布了新的文献求助10
6秒前
ruann完成签到 ,获得积分10
7秒前
王得胜完成签到,获得积分20
7秒前
惬意的晚风完成签到,获得积分10
7秒前
FashionBoy应助隐形觅翠采纳,获得10
7秒前
7秒前
闾丘曼安发布了新的文献求助30
8秒前
完美世界应助陌君子筱采纳,获得10
8秒前
8秒前
Xx完成签到,获得积分10
8秒前
Artsuhtaraz发布了新的文献求助10
9秒前
鞑靼发布了新的文献求助10
9秒前
优雅的念真完成签到,获得积分10
9秒前
Jemezs完成签到,获得积分10
9秒前
wonderting发布了新的文献求助10
9秒前
9秒前
陈chq发布了新的文献求助10
10秒前
11秒前
值雨完成签到,获得积分10
11秒前
11秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3148415
求助须知:如何正确求助?哪些是违规求助? 2799563
关于积分的说明 7835686
捐赠科研通 2456891
什么是DOI,文献DOI怎么找? 1307645
科研通“疑难数据库(出版商)”最低求助积分说明 628217
版权声明 601655